SCHOTT Pharma successfully executes its expansion strategy and invests in a new production facility in Serbia
Wednesday, December 20, 2023, Mainz, Germany
- SCHOTT Pharma’s products serve the growing market for injectable drugs
- The ramp-up is expected to start in the course of 2024
- More than 100 jobs will be created at the new site in Jagodina
The production site in Jagodina, a town of 35,000 inhabitants and the administrative center of the Pomoravlje County, is well on schedule: the groundbreaking ceremony will take place at the end of December. In the first phase, SCHOTT Pharma will create 130 new jobs, and 350 are planned for the expansion phase.
About SCHOTT PharmaSCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world – because human health matters. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,700 people from over 65 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 16 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house, a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. SCHOTT Pharma AG & Co. KGaA, headquartered in Mainz, Germany, is part of SCHOTT AG that is fully owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment and has the strategic goal of becoming climate-neutral by 2030. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenues of EUR 821m in the fiscal year 2022.
Manager Corporate Communications